Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.

BACKGROUND: A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients. METHODS: Patients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs). RESULTS: The geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8 months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89-9,571.94) U/mL (p = < 0.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63-27,227.01) U/mL (p < 0.0001) 1 month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8 months after the primary vaccine and 1 month after the booster dose were not significantly different (p > 0.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported. CONCLUSIONS: The majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events.

Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis.

Due to the nature of the disease, end-stage renal disease (ESRD) patients suffer from dysfunction of the adaptive immune system, which leads to a poorer response to vaccination. Accordingly, it is crucial to evaluate the efficacy and safety of management strategies, including vaccinations, which could potentially reduce the risk of respiratory diseases, such as pneumonia, influenza, or COVID-19, and its associated outcomes. We searched PubMed, CENTRAL, ScienceDirect, Scopus, ProQuest, and Google Scholar databases using designated MeSH keywords. The risk of bias was assessed using ROBINS-I. The quality of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Relative risk (RR) and 95% confidence interval (CI) were calculated. Heterogeneity was investigated using forest plots and I2 statistics. This systematic review included a total of 48 studies, with 13 studies of influenza (H1N1 and H3N2) vaccination and 35 studies of COVID-19 vaccination. H1N1 vaccination in ESRD patients undergoing hemodialysis induced lower seroconversion rates (RR 0.62, 95% CI: 0.56-0.68, p <0.00001) and lower seroprotection rates (RR 0.76, 95% CI: 0.70-0.83, p <0.00001) compared to controls. H3N2 vaccination in ESRD patients undergoing hemodialysis yielded lower seroconversion rates (RR 0.76, 95% CI: 0.68-0.85, p <0.00001) and lower seroprotection rates (RR 0.84, 95% CI: 0.77-0.90, p <0.00001) compared to controls. Twenty-nine studies demonstrate significantly lower antibody levels in ESRD patients undergoing hemodialysis compared to the controls following COVID-19 vaccination. This review presents evidence of lower seroconversion and seroprotection rates after vaccination against viral respiratory diseases in patients with ESRD undergoing hemodialysis. Since hemodialysis patients are more susceptible to infection and severe disease progression, a weakened yet substantial serological response can be considered adequate to recommend vaccination against respiratory diseases in this population. Vaccination dose, schedule, or strategy adjustments should be considered in stable ESRD patients on maintenance hemodialysis. Trial registration: Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021255983, identifier: CRD42021255983.

LOWER LEVEL OF INTERLEUKIN-6 AND HEPCIDIN FOUND IN LOWER DENSITY OF PHYSICAL EXERCISE AMONG ATHLETE DURING PANDEMIC OF COVID-19

The pandemic of Covid-19 affected entire daily human life worldwide, including sports activities among athletes. An athlete was pushed to suit their routine activities with a new health protocol for Covid-19 prevention. Some of them were programmed to train at home with a moderate density of exercise, but others were still in a high density of exercise. This study compared the serum level of hemoglobin (Hb), interleukin-6 (IL-6), and hepcidin among athletes with a high versus moderate exercise density training program during the pandemic. Thirty-four indoor soccer athletes of a soccer football school in Malang voluntarily registered as a subject. Half of them received moderate exercise density exercise programs, and others received high-density exercise programs during June-July 2020. Interleukin-6 and hepcidin level mean was found significantly lower in the moderate group compared to the high-density group. Hemoglobin level mean was found not different between those groups. The lower density of exercise influenced on IL-6 and hepcidin serum level of athlete, but not on hemoglobin level. (English) [ABSTRACT FROM AUTHOR] Pandemi Covid-19 berdampak luas terhadap semua sektor kehidupan dunia, termasuk terhadap kehidupan atlet yang aktif berolahraga. Atlet diwajbkan untuk menyesuaikan aktivitas latihan rutin dengan protokol kesehatan Covid-19. Sebagian dari atlet berlatih di rumah dengan porsi kepadatan yang dikurangi, karena takut terinfeksi penyakit Covid-19. Penelitian ini bertujuan untuk mengevaluasi kadar hemoglobin, interleukin-6 (IL-6) dan hepcidin dalam darah atlet yang memperoleh pengurangan porsi latihan dibandingkan dengan yang menerima porsi latihan tetap. Tiga puluh empat atlet futsal yang berasal dari dua kelompok SSB di Malang menjadi subjek penelitian. Sebagian dari mereka merupakan kelompok atlet yang memiliki kepadatan aktivitas berlatih tinggi (high) dan sebagian lainnya memiliki kepadatan aktivitas berlatih sedang (moderate). Kadar IL-6 dan hepcidin ditemukan lebih rendah secara bermakna dalam darah atlet kelompok atlet moderate dibandingkan dengan atlet yang high. Kadar hemoglobin tidak berbeda antara kedua kelompok atlet. Pengurangan kepadatan aktivitas berlatih atlet mempengaruhi kadar IL-6 dan hepcidin, namun tidak terhadap kadar hemoglobin. (Indonesian) [ABSTRACT FROM AUTHOR] Copyright of Folia Medica Indonesiana is the property of Folia Medica Indonesiana and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)